Journal of Clinical Oncology
Articles in this Issue
Dihydropyrimidine dehydrogenase (DPD) deficiency–related variants among Mexican patients with gastrointestinal (GI) malignancies.
1618 Background: DPD deficiency is the most important risk factor for developing fluoropyrimidine-related adverse events. Genetic variants causing DPD def...
Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project.
3007 Background: While circulating tumor DNA (ctDNA) demonstrates promise as a molecular residual disease (MRD) biomarker, its clinical implementation has...
A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.
6545 Background: A subset of patients (7-14%) with acute myeloid leukemia (AML) have mutations in the isocitrate dehydrogenase 1 gene (m IDH1...
Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors.
107 Background: Nectin-4 is a cell adhesion molecule that is highly expressed in a wide variety of cancers and is associated with poor prognosis. SHR-A210...
Comprehensive analysis on reactive cutaneous capillary endothelial proliferation following camrelizumab-based therapy in patients with solid tumors: A large-scale pooled analysis of nine phase 2 or phase 3 registration trials.
11037 Background: Previous studies demonstrated the positive association between cutaneous immune-related adverse events and long-term survival in advance...
Regional and socioeconomic disparities in Barrett’s esophagus and esophageal cancer mortality in the United States and Texas (1999-2023): A 24-year observational study.
e16144 Background: Barrett's esophagus (BE) elevates the risk of esophageal adenocarcinoma (EAC), by 30- fold above that of the general population. This s...
Molecular testing practice patterns for lung cancer based on gender: Insights into disparities and opportunities for precision medicine.
e20523 Background: Targeted and biomarker-driven immunotherapies have revolutionized outcomes of lung cancer, yet gender disparities may impact care. This...
Temporal trends in the incidence of non-Hodgkin lymphoma in the Middle East and North Africa over the past three decades.
e19071 Background: Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy globally, with rising incidence, particularly in high-income count...
Developing and implementing a fellow-driven communication skills curriculum in hematology/oncology training.
e21030 Background: Effective communication is essential in hematology/oncology (HO) for trust-building, shared decision-making, and simplifying complex me...
Are patients satisfied with the information in an informed consent form? Questionnaire-based study examining patients' viewpoints.
11021 Background: Ensuring that patients understand the information in an Informed Consent Form (ICF) is key to shared decision-making and ethical conduct...
Safety and efficacy evaluation of neoadjuvant chemoradiotherapy plus thymalfasin and tislelizumab for treating MSS/pMMR locally advanced rectal cancer.
3587 Background: Neoadjuvant chemoradiotherapy is currently the standard strategy for microsatellite stable (MSS) / mismatch repair-proficient (pMMR) loca...
Treatment of patients with locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) with cemiplimab as first-line systemic therapy in Slovenia.
e21516 Background: Immunotherapy has revolutionized the treatment of advanced malignancies, including CSCC. Cemiplimab, a PD-1 immune checkpoint inhibitor...
Phase II basket study to evaluate the tissue-agnostic efficacy of anti-PD1 in patients with advanced rare tumors: The ANTARES trial.
TPS2690 Background: Rare tumors account for 25-30% of all malignancies; however, patients (pts) with these cancers are underrepresented in clinical trials...
Phase I/II study to evaluate the feasibility and efficacy of sequential abemaciclib and gemcitabine treatment in patients with retinoblastoma (Rb)-positive leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLPS).
TPS11583 Background: LMS and DDLPS are aggressive malignancies with limited effective therapies in the advanced setting. Approximately 50% of LMS and near...
An automatic AI model for tumoral burden detection and segmentation on whole-body MRI: The DIPCAN study.
e13717 Background: Metastasis dissemination is the main cause of death from cancer, being whole-body magnetic resonance imaging (MRI) a key technology for...
Association of LIV-1 expression with clinical efficacy in patients with advanced breast cancers treated with BRY812.
e15005 Background: LIV-1 is a transmembrane protein that is involved in the transport of zinc ions across the cell membrane and exhibits metalloproteinase...
Effects of surgery on the prognosis of patients with locally advanced vulva cancer: A retrospective study of the SEER database and a Chinese multicentre registry.
5616 Background: Vulva cancer is a rare gynecologic oncology, and lacks uniform recommendations in current guidelines, especially for locally advanced cas...
Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial.
520 Background: Two years (yrs) of adjuvant abemaciclib + endocrine therapy (ET) resulted in sustained improvement in invasive disease-free survival (IDFS...
Comparing human-whole slide image (WSI) and AI-WSI assessment of tumor immune microenvironment in pleural mesothelioma: Insights from the ANEMONE Project.
e20096 Background: Tumor immune microenvironment (TIM) is critical in cancer progression and therapeutic response. In pleural mesothelioma (PM), the limit...
Impact of KRAS mutation status on outcomes in peritoneal metastatic mucinous adenocarcinoma of the colon and appendix following CRS-HIPEC: A retrospective analysis.
e15578 Background: KRAS mutations (MT) are seen in 40-45% of colon and 55% of appendiceal carcinoma. They are associated with poor prognosis in colon canc...
Characterization of leukemia inhibitory factor and its receptor in lung adenocarcinoma.
e20505 Background: In non-small cell lung cancer (NSCLC), including lung adenocarcinoma (LUAD), biomarker-driven therapy has become a cornerstone, but the...
Assessment of homologous recombination deficiency and BRCA status in ovarian cancer: Analytical performance and relevance of a decentralized NGS assay for comprehensive genomic profiling.
3130 Background: Homologous recombination deficiency (HRD) is a complex biomarker with predictive value in ovarian cancer. Understanding both the causes o...
Long-term follow-up of adjuvant DC-CIK following high-dose IFN versus high-dose IFN or anti-PD1 for resected acral/cutaneous melanoma.
e21571 Background: Novel individualized neoantigen vaccine showed durable survival benefit when combined with anti-PD-1(aPD-1) vs aPD-1 alone. Dendritic c...
Clinical characteristics and outcomes of metastatic germ cell tumors with highly elevated human chorionic gonadotropin levels.
e17018 Background: Serum human chorionic gonadotropin (hCG) levels greater than 50,000 in the pretreatment assessment of metastatic germ cell tumors (GCT)...
Exploring the clinical benefits of genomic profiling for advanced solid tumors in Portugal.
e23273 Background: Comprehensive genomic profiling (CGP) plays a significant role in precision oncology by pairing genomic alterations from different tumo...